• Suzhou Ribo Life Science Co. Ltd. recently announced that its siRNA partnership with Madrigal Pharmaceuticals achieved a first candidate drug nomination for RNA-based liver disease therapeutics targeting metabolic dysfunction-associated steatohepatitis (MASH), enabling the start of IND-enabling studies.
• This early-stage milestone underscores Madrigal’s push beyond its current MASH franchise, tapping a liver-targeted RNA platform aimed at a very large global patient population with limited treatment options.
• We’ll now examine how this new siRNA candidate for MASH could influence Madrigal’s investment narrative built largely around Rezdiffra’s outlook.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Madrigal Pharmaceuticals Investment Narrative Recap

To own Madrigal today, you need to believe Rezdiffra can anchor a durable MASH franchise while the company broadens beyond a single drug. The new siRNA candidate with Suzhou Ribo is encouraging for long term pipeline depth, but it does not change that near term sentiment still hinges on Rezdiffra’s commercialization progress and ongoing clinical data, with concentration in one asset remaining the core risk.

The most relevant recent update alongside this siRNA milestone is the new Rezdiffra data presented at EASL 2026, which reinforced signals on liver and cardiometabolic biomarkers in MASH. Together, stronger clinical evidence for Rezdiffra and a first RNA candidate nomination both feed into the same set of catalysts: how quickly physicians adopt Rezdiffra, how payers respond, and whether Madrigal can credibly show it is building a multi asset MASH platform rather than a one drug story.

Yet, in contrast, investors should also be aware that if Rezdiffra’s long term data or competitive pressures fall short of expectations, the company’s heavy single drug reliance could...

Madrigal Pharmaceuticals' narrative projects $3.2 billion revenue and $935.6 million earnings by 2029.

Uncover how Madrigal Pharmaceuticals' forecasts yield a $678.71 fair value, a 26% upside to its current price.

Exploring Other Perspectives

While consensus leans constructive, the lowest analyst estimates highlight that heavy dependence on Rezdiffra could still cap outcomes, even with the new siRNA news. Those analysts were previously modeling about US$2.9 billion in 2029 revenue and roughly US$600.4 million in earnings, which is a far more cautious path than some peers expect and could shift again as the RNA program progresses.

Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.